| Literature DB >> 33426379 |
Sasha Z Prisco1, Thenappan Thenappan1, Kurt W Prins1.
Abstract
Right ventricle (RV) dysfunction is the strongest predictor of mortality in pulmonary arterial hypertension (PAH), but, at present, there are no therapies directly targeting the failing RV. Although there are shared molecular mechanisms in both RV and left ventricle (LV) dysfunction, there are important differences between the 2 ventricles that may allow for the development of RV-enhancing or RV-directed therapies. In this review, we discuss the current understandings of the dysregulated pathways that promote RV dysfunction, highlight RV-enriched or RV-specific pathways that may be of particular therapeutic value, and summarize recent and ongoing clinical trials that are investigating RV function in PAH. It is hoped that development of RV-targeted therapies will improve quality of life and enhance survival for this deadly disease.Entities:
Keywords: FAO, fatty acid oxidation; IPAH, idiopathic pulmonary arterial hypertension; LV, left ventricle/ventricular; PAH, pulmonary arterial hypertension; PH, pulmonary hypertension; RAAS, renin-angiotensin-aldosterone system; RV, right ventricle/ventricular; RVH, right ventricular hypertrophy; SSc-PAH, systemic sclerosis-associated pulmonary arterial hypertension; clinical trials; miRNA/miR, micro-ribonucleic acid; pulmonary arterial hypertension; right ventricle
Year: 2020 PMID： 33426379 PMCID： PMC7775863 DOI： 10.1016/j.jacbts.2020.07.011
Source DB: PubMed Journal: JACC Basic Transl Sci ISSN： 2452-302X